Loading…
Loading…
Baby formula maker Nara Organics said it is voluntarily recalling all of its infant formula, currently available in the United States, over potential risk of bacterial contamination.
Mattress Firm Heats Up Summer Savings with its Annual July 4th Sale PR Newswire HOUSTON, June 10, 2026
CLPS Incorporation Restructures R&D Architecture, Introduces AI Rainstorm Factory Development Model PR Newswire
WHO-flagged Ebola outbreak and rising hantavirus exposure risks underscore growing institutional demand for scalable, hospital-grade decontamination solutions across healthcare, hospitality, transportation, and agricultural infrastructure. WHO-flagged Ebola outbreak and rising hantavirus exposure risks underscore growing institutional demand for scalable, hospital-grade decontamination solutions across healthcare, hospitality, transportation, and agricultural infrastructure.
Tarrytown, NY, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and Prevention (CDC) Hormone Standardization Program for Total Testosterone (HoSt-TT). This certifies that the Atellica IM TSTII immunoassay's test results are equivalent to high performance liquid chromatography coupled with tandem mass spectrometry, which is regarded as the gold‑standard analytical approach [1,2]. The Atellica IM TSTII assay, available on the Atellica IM and Atellica CI Analyzers, is the only fully automated immunoassay to achieve CDC HoSt-TT certification, which it has maintained continuously since 2019 [3]. An evaluation of the assay's performance was recently published in The Journal of Clinical Endocrinology & Metabolism.
Merck on Thursday said any changes to the U.S. child and adolescent immunization schedule should rest on comprehensive data and guidance from vaccine experts, after federal health officials shifted several shots out of the "universally recommended" category.
GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional financial support to continue progressing the Africa CDC-led ‘MpOx Study in Africa' (MOSA).
The VictoryShares US EQ Income Enhanced Volatility Wtd ETF receives a 'sell' rating due to fundamental portfolio weaknesses and an unreliable long/cash strategy. CDC has given up its lead over its 100% equity benchmark, represented by CDL, since its success rotation into treasuries in Q1 2020. Its 3.44% estimated dividend yield is reasonably attractive but no better than peers like LVHD, SPHD, and SCHD. Notably, SCHD has delivered superior total and downside risk-adjusted returns.